152 related articles for article (PubMed ID: 25739391)
1. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines.
Choi SH; Park BK; Lee KW; Chang J; Lee Y; Kwon HJ
BMB Rep; 2015 Oct; 48(10):565-70. PubMed ID: 25739391
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
4. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
6. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
[TBL] [Abstract][Full Text] [Related]
7. Fighting fire with fire: effects of oncolytic virotherapy on underlying viral hepatitis in hepatocellular carcinoma.
Reid T
Mol Ther; 2008 Sep; 16(9):1521-3. PubMed ID: 18725877
[No Abstract] [Full Text] [Related]
8. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Meng G; Li B; Chen A; Zheng M; Xu T; Zhang H; Dong J; Wu J; Yu D; Wei J
Br J Cancer; 2020 Jan; 122(1):111-120. PubMed ID: 31819179
[TBL] [Abstract][Full Text] [Related]
9. Anticancer oncolytic activity of respiratory syncytial virus.
Echchgadda I; Kota S; DeLa Cruz I; Sabbah A; Chang T; Harnack R; Mgbemena V; Chatterjee B; Bose S
Cancer Gene Ther; 2009 Dec; 16(12):923-35. PubMed ID: 19444304
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
Sagawa T; Yamada Y; Takahashi M; Sato Y; Kobune M; Takimoto R; Fukaura J; Iyama S; Sato T; Miyanishi K; Matsunaga T; Takayama T; Kato J; Sasaki K; Hamada H; Niitsu Y
Hepatology; 2008 Sep; 48(3):828-40. PubMed ID: 18756484
[TBL] [Abstract][Full Text] [Related]
11. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
12. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.
Zhang H; Li K; Lin Y; Xing F; Xiao X; Cai J; Zhu W; Liang J; Tan Y; Fu L; Wang F; Yin W; Lu B; Qiu P; Su X; Gong S; Bai X; Hu J; Yan G
Sci Transl Med; 2017 Aug; 9(404):. PubMed ID: 28835517
[TBL] [Abstract][Full Text] [Related]
13. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
Yoo SY; Badrinath N; Woo HY; Heo J
Mediators Inflamm; 2017; 2017():5198798. PubMed ID: 28512387
[TBL] [Abstract][Full Text] [Related]
15. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
17. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
18. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.
Choi JW; Kim HA; Nam K; Na Y; Yun CO; Kim S
J Control Release; 2015 Dec; 220(Pt B):691-703. PubMed ID: 26437261
[TBL] [Abstract][Full Text] [Related]
19. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
20. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
